ASH2022: A Novel Inhibitor of FLT3 and its Drug-resistant Mutants with Superior Activity to Gilteritinib in MOLM-13 Preclinical Acute Myeloid Leukemia Xenograft Model

Dec. 10

Written By Amy Burd

Download Publication

Amy Burd https://www.linkedin.com/in/amy-burd-4313813/

EILEAN THERAPEUTICS DOSES FIRST PATIENT WITH ZE46-0134, A SELECTIVE FLT3wt-SPARING, PAN FLT3mut INHIBITOR